We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Combined Laser and Nanotube Therapy Destroys Kidney Tumors

By HospiMedica International staff writers
Posted on 14 Aug 2009
A novel cancer treatment has been described that is based on carbon nanotubes that heat up when exposed to laser light and then destroy tumors into which they have been injected.

Investigators from Wake Forest University (Winston Salem, NC, USA) evaluated several protocols that involved injection of multiwalled carbon nanotubes (MWCNTs) directly into kidney tumors in a population of laboratory mice. More...
After injection of the nanotubes, the area of the tumors was subjected to various levels of laser light for different periods.

Data published in the July 20, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) revealed that injection of 100 micrograms of MWCNT followed by illumination for 30 seconds with a low power (three-watt) laser resulted in complete ablation of tumors and a more than nine month period of lasting remission in 80% of the mice. In contrast, mice that received no treatment, mice that received nanotubes with no laser treatment, and mice that received laser treatment without nanotubes died about 30 days into the study. The treatment caused minimal local toxicity with no evidence of systemic toxicity.

"You can actually watch the tumors shrinking until, one day, they are gone,” said senior author Dr. Suzy Torti, professor of biochemistry at Wake Forest University. "Not only did the mice survive, but they maintained their weight, did not have any noticeable behavioral abnormalities and experienced no obvious problems with internal tissues. As far as we can tell, other than a transient burn on the skin that did not seem to affect the animals and eventually went away, there were no real downsides--that is very encouraging. When dealing with cancer, survival is the endpoint that you are searching for. It is great if you can get the tumor to shrink, but the gold standard is to make the tumor shrink or disappear and not come back. It appears that we have found a way to do that.”

Related Links:
Wake Forest University



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.